Acacia Pharma Group Plc
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • California Compliance statement
    • Comprehensive Compliance Plan
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • California Compliance statement
    • Comprehensive Compliance Plan
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Contact

Transforming medicine

Advancing care

Home > News > Archive: 2018

Press Releases

12 December 2018

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

07 December 2018

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

21 November 2018

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

06 November 2018

Acacia Pharma Resubmits BARHEMSYS™ New Drug Application

06 November 2018

Unaudited Results for the nine months to 30 September 2018

15 October 2018

Further update on FDA regulatory review of BARHEMSYS™ 

08 October 2018

Update on FDA regulatory review of BARHEMSYS™

14 September 2018

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

07 September 2018

Interim Results for the First Half Year 2018

09 July 2018

Operating Update for the First Half 2018

02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

15 March 2018

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

04 January 2018

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

  • 1
  • 2
  • →
  • 2022 (5)
  • 2021 (16)
  • 2020 (18)
  • 2019 (13)
  • 2018 (14)
  • 2017 (1)
  • 2016 (3)
  • 2015 (4)
  • 2014 (1)
  • 2013 (4)
  • 2012 (3)
  • 2011 (7)
  • 2010 (1)
  • 2009 (5)
  • 2008 (3)
Acacia Pharma Group Plc
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map

© 2023 Acacia Pharma Group Plc

(Registered in England and Wales No: 09759376)
Registered office address: The Officers’ Mess, Royston Road, Duxford, Cambridge CB22 4QH, UK

Acacia Pharma Limited (Registered in England and Wales No: 05934843) and Acacia Pharma Inc (Incorporated under the laws of Delaware, No: 5799660) are members of the Acacia Pharma Group

Website by Instinctif Partners

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.